Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE- 048): a randomised, open-label, phase 3 study
- The Lancet [Internet] [cited 2020 Sep 20]. Accessed December 7, 2021: